When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
MYOV - Myovant +59% premarket after positive relugolix data in late-stage prostate study
Myovant Sciences Ltd.
Myovant Sciences (NYSE:MYOV) is up 59% premarket after the Phase 3 HERO study of once-daily, oral relugolix (120 mg) met its primary efficacy endpoint and all six key secondary endpoints in men with advanced prostate cancer.
More news on: Myovant Sciences Ltd., Healthcare stocks news, Stocks on the move,